Over six years after Glenmark re-organised its business into generic and speciality arms, the Mumbai-based drug-maker is looking to become one consolidated entity again. The company’s board has approved a proposal to merge Glenmark Pharmaceuticals’ subsidiaries - Glenmark Generics Ltd (GGL) and Glenmark Access Ltd (GAL) with the parent company. The merger will be through a court approved scheme of amalgamation, Glenmark Pharma said in its announcement to the BSE on Friday. As per the scheme, the remaining shareholders holding 0.67 per cent (10,16,741 equity shares) of the share capital of GGL will be issued shares of Glenmark Pharma at a swap ratio of four shares of Glenmark Pharma (of ₹1 each) for every five shares (of ₹10 each) held by the shareholders of GGL.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.